News

On the art of recommending eyeglasses to patients during the examination

Supplementation will keep the vitamin A levels above the critical threshold

Wound construction, IOL calculations, lens selection among variables in special population

On the rippling effects of alleviating suffering for free

Some older and newer treatments being studied for treating uveitis include iontophoresis, contact lenses, and nanoparticles.

Stephen J. Ryan, MD, a member of the Allergan Board of Directors, died on April 29, 2013 after a short illness.

A new PDUFA goal date has been established with the FDA for Iluvien fluocinolone acetonide implant (Alimera Sciences Inc.), and a PAS has been submitted to NICE in the United Kingdom.

EGP-437 (EyeGate Pharma), a corticosteroid formulation, was found to match the response rate to prednisolone acetate 1% for treatment of anterior uveitis.

New data show that a retinal prosthesis system is capable of providing face detection functionality to blind individuals, said Paulo E. Stanga, MD.

Symptomatic floaters can be safely and effectively treated with vitrectomy using 25-gauge instruments, and without inducing posterior vitreous detachment or removing the anterior vitreous, said Christianne A. Wa, a third-year medical student at USC School of Medicine, Los Angeles.

An estimated 25 million people in the United States have diabetes and face a higher risk for ophthalmic complications, including glaucoma, cataracts, and diabetic retinopathy. However, more than one-third of all persons in the United States with diabetes did not undergo an eye exam in the past year, said Fang Ko, MD.

One of the most unique aspects of the Association for Research in Vision and Ophthalmology (ARVO) meeting that ophthalmic clinicians won't find at any other meeting-including the American Academy of Ophthalmology (AAO) and American Society of Refractive and Cataract Surgery (ASCRS) meetings-is the poster sessions.

Pseudoexfoliation syndrome (PEX) appears to be significantly associated with both cardiovascular (CVD) and cerebrovascular disease (CVA), according to a new meta-analysis, said Helen Chung, MD.

The cost of caring for patients with glaucoma has risen in the past decade, but at a lower rate than that of general or medical inflation. For Medicare beneficiaries, the greatest expense was not the treatment for glaucoma per se, but rather for cataracts and retinal eye care, said Harry Quigley, MD.

As of Tuesday afternoon at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting, all of the head-to-head comparison studies involving the efficacy and the safety of ranibizumab (Lucentis) and bevacizumab (Avastin) are officially IN.

A novel investigational agent appears to help control uncomfortable symptoms of dry eye. The results of OPUS-I, a phase III randomized clinical trial, found that lifitegrast demonstrated superiority to placebo in reducing corneal fluorescein and conjunctival lissamine staining.

Ranibizumab and bevacizumab appear to be equally effective for the treatment age-related macular degeneration (AMD). The results of two large randomized multicenter trials-the IVAN and GEFAL-found that both drugs had similar effects on vision acuity and lesion morphology.

Adequate levels of vitamin D can decrease the risk of age-related macular degeneration (AMD), but most markedly in individuals with two risk alleles for the CFH Y402H genotype, said Amy Millen, PhD.

Primary open-angle glaucoma is generally associated with elevations in IOP, and damage to the cells residing within the trabecular meshwork is most likely a contributing factor, said Markus H. Kuehn, PhD.

Long-term results reveal that intravitreal ranibizumab (Lucentis, Genentech) has made a marked difference in the rates of blindness related to wet age-related macular degeneration (AMD), said Peter Cackett, MB BS.

The addition of the carotenoids, lutein and zeaxanthin, and the omega-3 fatty acids, DHA and EPA, to a supplement formulation does not further reduce the risk of disease progression in age-related macular degeneration (AMD), said Emily Y. Chew, MD.

The results of the long-awaited Age-Related Eye Disease Study 2 (AREDS2) were officially released Sunday afternoon during a special session at the Association for Research in Vision and Ophthalmology meeting in Seattle-and the study results really did not come as a surprise to most in the eye-care community.

Lens assessment with femtosecond laser imaging offers opportunity for cataract outcomes

Making a diagnosis is only the first step in treating dry eye syndrome

Pre-emptive strategies for exacerbations guided by seasonal fluctuations

Pre-existing dry eye should be identified and controlled before surgery is considered

Two cases illustrate benefits in managing dry eye before, after surgery with premium lens implantation

LASIK can be an option after management to normalize ocular surface